Suppr超能文献

PPARγ/PGC-1α与γ-GCS 在大鼠肺部及慢性阻塞性肺疾病患者中的相关性研究

Positive correlation between PPARgamma/PGC-1alpha and gamma-GCS in lungs of rats and patients with chronic obstructive pulmonary disease.

机构信息

Department of Respiratory Medicine, Hunan Institute of Gerontology, Hunan Province Geriatric Hospital, Changsha, China.

出版信息

Acta Biochim Biophys Sin (Shanghai). 2010 Sep;42(9):603-14. doi: 10.1093/abbs/gmq071. Epub 2010 Aug 7.

Abstract

Oxidative stress is one of the major pathogenesis of chronic obstructive pulmonary disease (COPD). gamma-Glutamylcysteine synthetase (gamma-GCS) is one of the paramount antioxidant enzymes in COPD. Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a ligand-activated transcription factor, which is activated by specific ligands such as rosiglitazone (RGZ), exerting multiple biological effects. PPARgamma coactivator-1alpha (PGC-1alpha) is a PPARgamma coactivator, which binds to PPARgamma by induction of PPARgamma ligands, co-activating PPARgamma target genes. Growing evidence has suggested that PPARgamma/PGC-1alpha can regulate multiple antioxidant genes. However, the effect of PPARgamma/PGC-1alpha on gamma-GCS during the development of COPD remains unclear. Here, we measured the expression levels of PPARgamma, PGC-1alpha and gamma-GCS, gamma-GCS activity and reactive oxygen species (ROS) contents in lungs of rats treated by cigarette smoke (CS) + lipopolysaccharide (LPS) and CS + LPS + RGZ, as well as lungs of patients suffered from COPD. Compared with lungs from CS + LPS-treated rats, lungs of RGZ-treated rats demonstrated markedly lower ROS contents, and remarkable increase of gamma-GCS activity and increase of the expression levels of PPARgamma, PGC-1alpha, and gamma-GCS. Furthermore, compared with controls, expression levels of PPARgamma, PGC-1alpha, and gamma-GCS significantly increased in the lungs of mild COPD patients, and progressively decreased in lungs of patients with moderate and severe COPD. gamma-GCS protein was positively correlated with FEV(1)%. PPARgamma and PGC-1alpha proteins were positively correlated with gamma-GCS activity and mRNA level. In conclusion, gamma-GCS showed compensatory upregulation in the early stage of COPD, which progressively decompensate with increasing COPD severity. The activation of the PPARgamma/PGC-1alpha pathway may protect against COPD progression by upregulating gamma-GCS and relieving oxidative stress.

摘要

氧化应激是慢性阻塞性肺疾病(COPD)的主要发病机制之一。γ-谷氨酰半胱氨酸合成酶(γ-GCS)是 COPD 中最重要的抗氧化酶之一。过氧化物酶体增殖物激活受体-γ(PPARγ)是一种配体激活的转录因子,被特定的配体如罗格列酮(RGZ)激活,发挥多种生物学作用。过氧化物酶体增殖物激活受体γ共激活因子-1α(PGC-1α)是一种 PPARγ 共激活因子,通过诱导 PPARγ 配体与 PPARγ 结合,共同激活 PPARγ 靶基因。越来越多的证据表明,PPARγ/PGC-1α可以调节多种抗氧化基因。然而,PPARγ/PGC-1α在 COPD 发展过程中对γ-GCS 的影响尚不清楚。在这里,我们测量了香烟烟雾(CS)+脂多糖(LPS)和 CS+LPS+RGZ 处理的大鼠肺中 PPARγ、PGC-1α 和 γ-GCS 的表达水平、γ-GCS 活性和活性氧(ROS)含量,以及患有 COPD 的患者的肺。与 CS+LPS 处理的大鼠肺相比,RGZ 处理的大鼠肺中的 ROS 含量明显降低,γ-GCS 活性显著增加,PPARγ、PGC-1α 和 γ-GCS 的表达水平增加。此外,与对照组相比,轻度 COPD 患者肺中 PPARγ、PGC-1α 和 γ-GCS 的表达水平显著增加,而中度和重度 COPD 患者肺中则逐渐降低。γ-GCS 蛋白与 FEV1%呈正相关。PPARγ 和 PGC-1α 蛋白与 γ-GCS 活性和 mRNA 水平呈正相关。总之,γ-GCS 在 COPD 的早期阶段表现出代偿性上调,随着 COPD 严重程度的增加而逐渐失代偿。PPARγ/PGC-1α 通路的激活可能通过上调 γ-GCS 和减轻氧化应激来保护 COPD 进展。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验